Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Vivos Therapeutics (VVOS) Receivables - Net (2019 - 2025)

Vivos Therapeutics' Receivables - Net history spans 7 years, with the latest figure at $1.6 million for Q4 2025.

  • Quarterly results put Receivables - Net at $1.6 million for Q4 2025, up 267.67% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 267.67% YoY), and the annual figure for FY2025 was $1.6 million, up 267.67%.
  • Receivables - Net for Q4 2025 was $1.6 million at Vivos Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $3.8 million in Q3 2021 to a low of $202000.0 in Q4 2023.
  • The 5-year median for Receivables - Net is $754500.0 (2022), against an average of $1.1 million.
  • The sharpest move saw Receivables - Net crashed 77.41% in 2022, then surged 370.04% in 2025.
  • Year by year, Receivables - Net stood at $1.2 million in 2021, then plummeted by 62.01% to $457000.0 in 2022, then plummeted by 55.8% to $202000.0 in 2023, then skyrocketed by 112.87% to $430000.0 in 2024, then soared by 267.67% to $1.6 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $1.6 million, $2.1 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.